HALO
Halozyme Therapeutics
Biological Products, (No Diagnostic Substances) · Health Care
$128.62-0.26%
Quote via Yahoo Finance, may be delayed · 2026-11-03 · 4:00 PM ET
Daily prices: Yahoo Finance, split-adjusted. As of 2026-11-03.
Drag across the line to read a price. Dots mark earnings, filings and dividends.
Strong profile
Revenue CAGR, 3Y lifts this profile the most.
As of 2025-12-31. Latest quarter ended 2026-06-30. v1 methodology, subject to change.
The profile score is 2 points lower since last quarter. Cash is 25 points higher. Price is 23 points lower.
Sector rank 3 of 46
In plain English
- Halozyme Therapeutics operates in Biological Products, (No Diagnostic Substances).
- Latest-year revenue was 1.4 billion.
- The profile score is 70, a Strong profile. Growth is the strongest listed input.
Written from the figures on this page. No language model was called. It may still be wrong. Not advice.
As of 2025-12-31. Latest quarter ended 2026-06-30. SEC EDGAR companyfacts, fetched 2026-11-01. SEC filing
Financials
Tap a column to read the value.
P/E vs own history
Now 38.5 times, 5-year median 18.3 times.
Line is the quarterly multiple. The band is the 25th to 75th percentile of that history. The dashed line is the median.
Earnings
Actual earnings per share from EDGAR filings. Historical estimates are not used.
Actual from EDGAR
Data confidence
The Company Score summarises financial characteristics relative to similar companies using a published formula. It does not predict future returns.
SEC EDGAR companyfacts, fetched 2026-11-01.